Epcoritamab treatment for chronic lymphocytic leukemia and Richter syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of epcoritamab on chronic lymphocytic leukemia (CLL) and Richter syndrome by analyzing lymph node, bone marrow, and blood samples from participants. Patients enrolled in a related trial will undergo various procedures, including biopsies and blood draws, to evaluate the pharmacodynamic effects of the treatment. The study aims to assess how epcoritamab influences the tumor microenvironment and clonal dynamics, with a focus on identifying biomarkers that could enhance treatment efficacy.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Must be undergoing screening for GCT3013-03
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

None

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Clare C Sun, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Ingrid C Frey
• Email: ingrid.frey@nih.gov
• Phone: (301) 312-0765

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP for DLBCL-type Richter Transformation in older or frail adults

  This trial tests a fixed-duration treatment with Pirtobrutinib and Epcoritamab against a mini-CHOP regimen in adults age 80+ or who are frail with Richter transformation.

  Recruiting at 7 sites Phase 2 German CLL Study Group · Melbourne and 11 other locations · NCT07917780

• Low-dose epcoritamab with GemOx for relapsed/refractory DLBCL

  This trial will test whether adding a low dose of epcoritamab to GemOx chemotherapy helps people with relapsed or refractory diffuse large B‑cell lymphoma who are eligible for autologous stem cell transplant.

  Recruiting Phase 2 Hospital Universitario Dr. Jose E. Gonzalez · Monterrey, Nuevo León · NCT07451652

• Epcoritamab plus R-GemOx before autologous stem cell transplant for relapsed or refractory DLBCL

  This phase II trial tests whether adding epcoritamab to rituximab with gemcitabine and oxaliplatin (R-GemOx) can help adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) achieve remission and proceed to autologous stem cell transplant.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07365306

• NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma

  This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283679

• Pirtobrutinib added to R-CHOP for newly diagnosed Richter transformation in Lymphoma

  This trial tests whether adding pirtobrutinib to the standard R-CHOP treatment helps people with Richter transformation (a CLL/SLL that becomes aggressive LBCL).

  Recruiting at 62 sites Phase 3 SWOG Cancer Research Network · Irvine, California and 61 other locations · NCT07220187

• Venetoclax plus obinutuzumab followed by epcoritamab for untreated CLL/SLL

  This trial tests whether giving venetoclax and obinutuzumab followed by epcoritamab can produce deep remissions in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 6 other locations · NCT07218510

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.